| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.048 | 0.8 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.8 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.0067 | 0.8 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | -0.0071 | 0.8 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.0067 | 0.8 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |